Geode Capital Management LLC Purchases 212,394 Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)

Geode Capital Management LLC increased its position in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 70.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 515,006 shares of the medical device company’s stock after buying an additional 212,394 shares during the quarter. Geode Capital Management LLC owned 0.37% of Xtant Medical worth $348,000 as of its most recent SEC filing.

Separately, Evernest Financial Advisors LLC acquired a new position in Xtant Medical during the 3rd quarter worth approximately $27,000. 69.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Craig Hallum set a $1.50 price objective on shares of Xtant Medical and gave the stock a “buy” rating in a research report on Friday, October 18th.

Xtant Medical Trading Up 6.7 %

XTNT opened at $0.50 on Monday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.88 and a current ratio of 2.12. The stock has a market cap of $69.34 million, a P/E ratio of -3.84 and a beta of 0.34. Xtant Medical Holdings, Inc. has a 52-week low of $0.33 and a 52-week high of $1.30.

Xtant Medical (NYSEAMERICAN:XTNT) last released its quarterly earnings data on Tuesday, November 12th. The medical device company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The company had revenue of $27.94 million during the quarter. Xtant Medical had a negative net margin of 15.45% and a negative return on equity of 37.07%.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.